REGMF Stock - RemeGen Co., Ltd.
Unlock GoAI Insights for REGMF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.71B | $1.08B | $767.77M | $1.42B | N/A |
| Gross Profit | $1.37B | $822.99M | $497.84M | $1.36B | N/A |
| Gross Margin | 80.0% | 76.5% | 64.8% | 95.3% | N/A |
| Operating Income | $-1,370,828,000 | $-1,502,346,000 | $-1,054,079,000 | $162.84M | $-637,242,000 |
| Net Income | $-1,468,362,000 | $-1,511,229,000 | $-998,830,000 | $276.26M | $-697,821,000 |
| Net Margin | -85.9% | -140.4% | -130.1% | 19.4% | N/A |
| EPS | $-2.73 | $-2.80 | $-1.88 | $0.57 | $-1.71 |
RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.
Visit WebsiteEarnings History & Surprises
REGMFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 25, 2026 | — | — | — | — |
Q4 2025 | Oct 30, 2025 | — | $-0.03 | — | — |
Q3 2025 | Aug 22, 2025 | — | $-0.05 | — | — |
Q2 2025 | Apr 28, 2025 | — | $-0.06 | — | — |
Q4 2024 | Dec 31, 2024 | — | $-0.10 | — | — |
Q4 2024 | Oct 29, 2024 | — | $-0.08 | — | — |
Q3 2024 | Aug 16, 2024 | — | $-0.11 | — | — |
Q2 2024 | Apr 26, 2024 | — | $-0.09 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.13 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.08 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.10 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.09 | — | — |
Q1 2023 | Feb 27, 2023 | — | $-0.08 | — | — |
Q4 2022 | Oct 27, 2022 | — | $-0.05 | — | — |
Q3 2022 | Aug 30, 2022 | — | $-0.06 | — | — |
Q2 2022 | Apr 27, 2022 | — | $-0.09 | — | — |
Q4 2021 | Dec 31, 2021 | — | $0.31 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.08 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.08 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.06 | — | — |
Latest News
Vor Bio's Collaborator, RemeGen, Presents 48-Week Open-Label Extension Data From Phase 3 Study In China Evaluating Telitacicept In Patients With gMG At AANEM Annual Meeting
➖ NeutralVor Bio Announces Publication Of Results From Phase 3 Study In China Evaluating Telitacicept In SLE Sponsored By Collaborator, RemeGen, In New England Journal Of Medicine
📈 PositiveVor Bio Announces That Collaborator Remegen Reported 48-Week Phase 3 Results From Its Study In Primary Sjögren's Disease, Showing That Telitacicept Met All Primary And Secondary Endpoints With High Statistical Significance At Weeks 24 And 48
📈 PositiveReported Earlier, RemeGen Announces Oral Presentation Of Phase III Telitacicept Study Results For Generalized Myasthenia Gravis At AANEM 2025
➖ NeutralVor Bio Reports RemeGen's Telitacicept Meets Primary Endpoint In IgAN Phase 3 Trial; RemeGen To Submit BLA For Telitacicept in IgAN
📈 PositiveVor Bio, RemeGen succeed in trial for telitacicept in China
📈 PositiveVor Bio surges after private placement, licensing deal
📈 PositiveFrequently Asked Questions about REGMF
What is REGMF's current stock price?
What is the analyst price target for REGMF?
What sector is RemeGen Co., Ltd. in?
What is REGMF's market cap?
Does REGMF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to REGMF for comparison